Lead clinical products
NP213 (Novexatin®) Phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis) being co-developed with the Company’s global licensing partner, Taro Pharmaceuticals.
NM001 (Lynovex®) A unique dual antibacterial-mucolytic orphan drug candidate in late stage clinical evaluation for cystic fibrosis.
Pipeline and Partnering
NovaBiotics is developing its robust pipeline of antibacterial and antifungal candidates for medically unmet conditions with significant market potential to early/mid clinical proof of concept, before out-licensing or securing co-development partnerships.
NovaBiotics will be attending and presenting at the conference listed above